The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
Open accessAbstract
The common participation of oncogenic KRAS proteins in many of the most lethal human cancers, together with the ease of detecting somatic KRAS mutant alleles in patient samples, has spurred persistent and intensive efforts to develop drugs that inhibit KRAS activity. However, advances have been hindered by the pervasive inter- and intra-lineage diversity in the targetable mechanisms that underlie KRAS-driven cancers, limited pharmacological accessibility of many candidate synthetic-lethal interactions and the swift emergence of unanticipated resistance mechanisms to otherwise effective targeted therapies. Here we demonstrate the acute and specific cell-autonomous addiction of KRAS-mutant non-small-cell lung cancer cells to receptor-dependent nuclear export. A multi-genomic, data-driven approach, utilizing 106 human non-small-cell lung cancer cell lines, was used to interrogate 4,725 biological processes with 39,760 short interfering RNA pools for those selectively required for the survival of KRAS-mutant cells that harbour a broad spectrum of phenotypic variation. Nuclear transport machinery was the sole process-level discriminator of statistical significance. Chemical perturbation of the nuclear export receptor XPO1 (also known as CRM1), with a clinically available drug, revealed a robust synthetic-lethal interaction with native or engineered oncogenic KRAS both in vitro and in vivo. The primary mechanism underpinning XPO1 inhibitor sensitivity was intolerance to the accumulation of nuclear IκBα (also known as NFKBIA), with consequent inhibition of NFκB transcription factor activity. Intrinsic resistance associated with concurrent FSTL5 mutations was detected and determined to be a consequence of YAP1 activation via a previously unappreciated FSTL5-Hippo pathway regulatory axis. This occurs in approximately 17% of KRAS-mutant lung cancers, and can be overcome with the co-administration of a YAP1-TEAD inhibitor. These findings indicate that clinically available XPO1 inhibitors are a promising therapeutic strategy for a considerable cohort of patients with lung cancer when coupled to genomics-guided patient selection and observation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The pervasive diversity of this oncogenotype was aptly demonstrated in a study that applied affinity propagation clustering analysis36 to mRNA expression data from 106 genomically-annotated NSCLC cell lines; strikingly, variation in mRNA expression within KRAS-mutant NSCLC cell lines was equivalent to that observed across the entire cell line panel37.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Clustering by Passing Messages Between Data Points
Frey, B. J., & Dueck, D. (2007) · Science · doi:10.1126/science.1136800 · Cited by 6,855
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citationHippo pathway in organ size control, tissue homeostasis, and cancer
Yu, F.-X., Zhao, B., & Guan, K.-L. (2015) · Cell · doi:10.1016/j.cell.2015.10.044 · Cited by 2,206
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity
Jackson, A. L., Burchard, J., Schelter, J. M., Chau, B. N., Cleary, M. A., Lim, L. P., & Linsley, P. S. (2006) · RNA · doi:10.1261/rna.25706 · Cited by 979
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M. J. P., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 873
Cited by
Sorted by citations
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Ambrogio, C., Köhler, J., Zhou, Z.-W., Wang, H., Paranal, R., Li, J., Capelletti, M., Caffarra, C., Li, S., Lv, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.020 · Cited by 270
Targeting Oncogenic BRAF: Past, Present, and Future
Zaman, A., Wu, W., & Bivona, T. G. (2019) · Cancers · doi:10.3390/cancers11081197 · Cited by 252
XPO1-dependent nuclear export as a target for cancer therapy
Azizian, N. G., & Li, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00903-4 · Cited by 247
Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells
Chen, P.-H., Cai, L., Huffman, K. E., Yang, C., Kim, J., Faubert, B., Boroughs, L. K., Ko, B., Sudderth, J., McMillan, E. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.028 · Cited by 209
Self-citationKRAS G12C inhibition produces a driver-limited state revealing collateral dependencies
Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9450 · Cited by 175
RAS: Striking at the Core of the Oncogenic Circuitry
Gimple, R. C., & Wang, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00965 · Cited by 174
Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization
Pinarbasi, E. S., Çağatay, T., Fung, H. Y. J., Li, Y. C., Chook, Y. M., & Thomas, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-25008-4 · Cited by 180
The Hippo pathway in normal development and cancer
Maugeri‐Saccà, M., & Maria, R. D. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.011 · Cited by 169
Network-based integration of multi-omics data for prioritizing cancer genes
Dimitrakopoulos, C. M., Hindupur, S. K., Häfliger, L., Behr, J., Montazeri, H., Hall, M. N., & Beerenwinkel, N. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty148 · Cited by 166
Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer
McMillan, E. A., Ryu, M.-J., Diep, C. H., Mendiratta, S., Clemenceau, J. R., Vaden, R. M., Kim, J.-H., Motoyaji, T., Covington, K. R., Peyton, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.028 · Cited by 141
Self-citationThe roles of the nuclear pore complex in cellular dysfunction, aging and disease
Sakuma, S., & D’Angelo, M. A. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.05.006 · Cited by 133
Çağatay, T., & Chook, Y. M. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2018.01.006 · Cited by 123
Koundinya, M., Sudhalter, J., Courjaud, A., Lionne, B., Touyer, G., Bonnet, L., Menguy, I., Schreiber, I., Perrault, C., Vougier, S., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.03.005 · Cited by 123
The Evolutionary Origins of Recurrent Pancreatic Cancer
Sakamoto, H., Attiyeh, M. A., Gerold, J. M., Makohon-Moore, A. P., Hayashi, A., Hong, J., Kappagantula, R. L., Zhang, L., Melchor, J. P., Reiter, J. G., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1508 · Cited by 123
Neggers, J. E., Kwanten, B., Dierckx, T., Noguchi, H., Voet, A. R. D., Bral, L., Minner, K., Massant, B., Kint, N., Delforge, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02349-8 · Cited by 115
Self-citationNuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals
Fung, H. Y. J., Fu, S.-C., & Chook, Y. M. (2017) · eLife · doi:10.7554/elife.23961 · Cited by 99
Patient-derived cell line, xenograft and organoid models in lung cancer therapy
Huo, K.-G., D’Arcangelo, E., & Tsao, M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-154 · Cited by 98
The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor
Wei, C., & Li, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.557429 · Cited by 93
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
Camus, V., Miloudi, H., Taly, A., Sola, B., & Jardin, F. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0412-4 · Cited by 96
Synthetic Lethality and Cancer – Penetrance as the Major Barrier
Ryan, C. J., Bajrami, I., & Lord, C. J. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.08.003 · Cited by 91
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Tsuji, T., Ozasa, H., Aoki, W., Aburaya, S., Funazo, T. Y., Furugaki, K., Yoshimura, Y., Yamazoe, M., Ajimizu, H., Yasuda, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13771-5 · Cited by 79
TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer
Cooper, J. M., Ou, Y.-H., McMillan, E. A., Vaden, R. M., Zaman, A., Bodemann, B. O., Makkar, G., Posner, B. A., & White, M. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0829 · Cited by 79
Self-citationKRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Xie, M., Xu, X., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672612 · Cited by 80
Machlus, K. R., Wu, S., Vijey, P., Soussou, T. S., Liu, Z.-J., Shacham, E., Unger, T. J., Kashyap, T., Klebanov, B., Sola-Visner, M. C., et al. (2017) · Blood · doi:10.1182/blood-2016-11-752840 · Cited by 74
Self-citationTargeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 74
Nuclear export of RNA: Different sizes, shapes and functions
Williams, T. D., Ngo, L. H., & Wickramasinghe, V. O. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.08.054 · Cited by 69
Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer
Vlahopoulos, S., Adamaki, M., Khoury, N., Zoumpourlis, V. C., & Boldogh, I. R. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.004 · Cited by 68
Nguyen, T., & Barr, F. G. (2018) · Molecules · doi:10.3390/molecules23112798 · Cited by 69
The nucleoporin ELYS regulates nuclear size by controlling NPC number and nuclear import capacity
Jevtić, P., Schibler, A. C., Wesley, C. C., Pegoraro, G., Misteli, T., & Levy, D. L. (2019) · EMBO Reports · doi:10.15252/embr.201847283 · Cited by 61
Inhibition of Nuclear Pore Complex Formation Selectively Induces Cancer Cell Death
Sakuma, S., Raı́ces, M., Borlido, J., Guglielmi, V., Zhu, E. Y. S., & D’Angelo, M. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0581 · Cited by 60
The NDR/LATS protein kinases in immunology and cancer biology
Sharif, A. A. D., & Hergovich, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.010 · Cited by 60
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 67
Wang, C., Li, J., Chen, J., Wang, Z., Zhu, G., Song, L., Wu, J., Li, C., Qiu, R., Chen, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55068-2 · Cited by 59
Tpr regulates the total number of nuclear pore complexes per cell nucleusPreprint
McCloskey, A., Ibarra, A., & Hetzer, M. W. (2018) · Genes & Development · doi:10.1101/gad.315523.118 · Cited by 53
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
Quintanal-Villalonga, A., Taniguchi, H., Hao, Y., Chow, A. T., Zhan, Y. A., Chavan, S. S., Uddin, F., Allaj, V., Manoj, P., Shah, N. S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2964 · Cited by 51
Saenz-Ponce, N., Pillay, R. R., de Long, L. M., Kashyap, T., Argueta, C. E., Landesman, Y., Hazar-Rethinam, M. H., Boros, S., Panizza, B. J., Jacquemyn, M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7223 · Cited by 51
Self-citationThy-1+ Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis
Schliekelman, M. J., Creighton, C. J., Baird, B. N., Chen, Y., Banerjee, P., Bota‐Rabassedas, N., Ahn, Y., Roybal, J. D., Chen, F., Zhang, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06922-5 · Cited by 49
Self-citationLi, D., Chen, W., Luo, L., Wang, Y., Shang, J., Zhang, Y., Chen, G., & Li, S. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3187 · Cited by 48
Wahba, A., Rath, B. H., O'Neill, J. W., Camphausen, K. A., & Tofilon, P. J. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1303 · Cited by 47
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma
Nokin, M., Darbo, É., Travert, C., Drogat, B., Lacouture, A., José, S. S., Cabrera-Benítez, N. E., Turcq, B., Prouzet‐Mauleon, V., Falcone, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137869 · Cited by 47
Lin, K., Rutter, J. C., Xie, A., Killarney, S. T., Vaganay, C., Benaksas, C., Ling, F., Sodaro, G., Meslin, P.-A., Bassil, C. F., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00394-x · Cited by 49
Marini, K. D., Croucher, D. R., McCloy, R. A., Vaghjiani, V., González-Rajal, Á., Hastings, J. F., Chin, V. T., Szczepny, A., Kostyrko, K., Márquez, C. P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3504 · Cited by 45
Zhu, Z., Liu, J., Yang, C., Zhao, M., & Xiong, Z. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1627-9 · Cited by 45
Zhang, W., Lu, Y., Li, X., Zhang, J., Lin, W., Zheng, L., Zheng, L., & Li, X. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1290-0 · Cited by 45
Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors
Conforti, F., Zhang, X., Rao, G., Pas, T. M. D., Yonemori, Y., Rodríguez, J. A., McCutcheon, J. N., Rahhal, R., Alberobello, A. T., Wang, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1323 · Cited by 44
Along the Central Dogma—Controlling Gene Expression with Small Molecules
Schneider‐Poetsch, T., & Yoshida, M. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-033923 · Cited by 44
Chanukuppa, V., Paul, D., Taunk, K., Chatterjee, T., Sharma, S., Kumar, S., Santra, M. K., & Rapole, S. (2019) · Journal of Proteomics · doi:10.1016/j.jprot.2019.103504 · Cited by 42
KRAS: A Promising Therapeutic Target for Cancer Treatment
Wu, H.-Z., Xiao, J., Xiao, S., & Cheng, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190905164144 · Cited by 41
Hiramitsu, S., Ishikawa, T., Lee, W.-R., Khan, T., Crumbley, C., Khwaja, N., Zamanian, F., Asghari, A., Şen, M., Zhang, Y., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00470 · Cited by 40
Self-citationInoue, A., Robinson, F. S., Minelli, R., Tomihara, H., Rizi, B. S., Rose, J. L., Kodama, T., Srinivasan, S., Harris, A. L., Zuniga, A. M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.03.022 · Cited by 40
Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer
Vichas, A., Riley, A. K., Nkinsi, N. T., Kamlapurkar, S., Parrish, P. C. R., Lo, A., Duke, F. F., Chen, J., Fung, I., Watson, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24841-y · Cited by 43
Pooled multicolour tagging for visualizing subcellular protein dynamics
Reicher, A., Reiniš, J., Ciobanu, M., Růžička, P., Malik, M., Siklos, M. I., Kartysh, V., Tomek, T., Koren, A., Rendeiro, A. F., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01407-w · Cited by 39
Wu, J., Zhao, Q., Chen, S., Xu, H., Zhang, R., Cai, D., Gao, Y., Peng, W., Chen, X., Yuan, S., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217266 · Cited by 40
Ku, A. A., Hu, H., Zhao, X., Shah, K. N., Kongara, S., Wu, D., McCormick, F. P., Balmain, A., & Bandyopadhyay, S. (2020) · Nature Communications · doi:10.1038/s41467-020-16078-y · Cited by 38
Li, X., & Gu, Y. (2020) · Current Opinion in Plant Biology · doi:10.1016/j.pbi.2020.10.006 · Cited by 41
Beck, M., Schirmacher, P., & Singer, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.021 · Cited by 37
Targeting KRAS in PDAC: A New Way to Cure It?
He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 39
Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer
Gupta, A., Saltarski, J. M., White, M. A., Scaglioni, P. P., & Gerber, D. E. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.06.013 · Cited by 34
Self-citationTanaka, I., Sato, M., Kato, T., Goto, D., Kakumu, T., Miyazawa, A., Yogo, N., Hase, T., Morise, M., Sekido, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13602 · Cited by 34
Self-citationKarimi, N., & Moghaddam, S. J. (2023) · Cells · doi:10.3390/cells12050749 · Cited by 37
Hsu, P., Tian, B., Yang, Y., Wang, Y., Liu, S., Urisman, A., Yang, C., Xu, Z., Jablons, D. M., & You, L. (2019) · Oncology Reports · doi:10.3892/or.2019.7207 · Cited by 32
Oncoprotein-specific molecular interaction maps (SigMaps) for cancer network analyses
Broyde, J., Simpson, D. R., Murray, D., Paull, E., Chu, B., Tagore, S., Jones, S. J., Griffin, A. T., Giorgi, F. M., Lachmann, A., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0652-7 · Cited by 33
RNA-binding proteins of COSMIC importance in cancer
Choi, P. S., & Thomas‐Tikhonenko, A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151627 · Cited by 32
Hsu, P., Miao, J., Huang, Z., Yang, Y., Xu, Z., You, J., Dai, Y., Yeh, C., Chan, G., Liu, S., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13582 · Cited by 32
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment
Zaman, A., & Bivona, T. G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.02 · Cited by 29
CRM1-spike-mediated nuclear export of hepatitis B virus encapsidated viral RNA
Yang, C.-C., Chang, C.-H., Chen, H., Chou, M.-C., Yang, C., Jhou, R., Huang, E.-Y., Li, H.-C., Suen, C., Hwang, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110472 · Cited by 29
Genome-wide DNA methylation analysis of KRAS mutant cell lines
Tew, B. Y., Durand, J. K., Bryant, K. L., Hayes, T. K., Peng, S., Tran, N. L., Gooden, G. C., Buckley, D. N., Der, C. J., Baldwin, A. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66797-x · Cited by 29
Khan, H. Y., Nagasaka, M., Li, Y., Aboukameel, A., Uddin, M. H., Sexton, R. E., Bannoura, S. F., Mzannar, Y., Hallak, M. N. A., Kim, S. H., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0176 · Cited by 27
Self-citationHigh-throughput functional annotation of natural products by integrated activity profiling
Hight, S. K., Clark, T. N., Kurita, K. L., McMillan, E. A., Bray, W. M., Shaikh, A. F., Khadilkar, A., Haeckl, F. P. J., Neto, F. C., La, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208458119 · Cited by 27
Self-citationZhang, D., Zhang, W., Liu, W., Mao, Y., Fu, Z., Liu, J., Huang, W., Zhang, Z., An, D., & Li, B. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.06.008 · Cited by 27
Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
Zhang, Y., Liang, S., Zhao, L., Yang, H., Marti, T. M., Hegedűs, B., Gao, Y., Zheng, B., Chen, C., Wang, W., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02240-5 · Cited by 28
The STK38–XPO1 axis, a new actor in physiology and cancer
Martin, A. P. J., Aushev, V. N., Zalcman, G., & Camonis, J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03690-w · Cited by 25
Rosen, J. C., Weiss, J., Pham, N., Li, Q., Martins-Filho, S. N., Wang, Y., Tsao, M., & Moghal, N. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101179 · Cited by 25
Sendino, M., Ibarra, M. J. O., & Rodríguez, J. A. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.09 · Cited by 24
Li, C., Dai, L., Zhang, J., Zhang, Y., Lin, Y., Cheng, L., Tian, H., Zhang, X., Wang, Q., Yang, Q., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13906 · Cited by 24
Abboud, R., Chendamarai, E., Rettig, M. P., Trinkaus, K. M., Riedell, P. A., Abboud, C. N., Ghobadi, A., Pusic, I., Stockerl-Goldstein, K. E., Schroeder, M. A., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.236810 · Cited by 24
Liu, K., Guo, J., Liu, K., Fan, P., Zeng, Y., Xu, C., Zhong, J., Li, Q., & Zhou, Y. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.034 · Cited by 23
Turner, J. G., Cui, Y., Bauer, A. A., Dawson, J. L., Gomez, J. A., Kim, J., Cubitt, C. L., Nishihori, T., Dalton, W. S., & Sullivan, D. M. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-0677 · Cited by 23
Self-citationThe nuclear export protein exportin‐1 in solid malignant tumours: From biology to clinical trials
Lai, C., Xu, L., & Dai, S. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1684 · Cited by 25
Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures
Satpathy, S., Clark, N. M., Chen, Y., Hosseini, N., Chang, Y.-H., Hsiao, Y., Lei, J. T., Petralia, F., Chen, J., Geffen, Y., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.011 · Cited by 23
The SINE Compound KPT-350 Blocks Dystrophic Pathologies in DMD Zebrafish and Mice
Hightower, R. M., Reid, A. L., Gibbs, D. E., Wang, Y., Widrick, J. J., Kunkel, L. M., Kastenschmidt, J. M., Villalta, S. A., van Groen, T., Chang, H., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.016 · Cited by 22
Self-citationZhu, G., Zhang, Y., Wang, Q., Che, S., Yang, Y., Chen, L., & Lin, Z. (2019) · Cancer Management and Research · doi:10.2147/cmar.s195093 · Cited by 21
Ki, D. H., Oppel, F., Durbin, A. D., & Look, A. T. (2019) · Oncogene · doi:10.1038/s41388-019-0965-5 · Cited by 21
Liu, W., Cao, H., Wang, J., Elmusrati, A., Han, B., Chen, W., Zhou, P., Li, X., Keysar, S. B., Jimeno, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50861-5 · Cited by 21
Nucleocytoplasmic Shuttling of STATs. A Target for Intervention?
Ernst, S., & Müller‐Newen, G. (2019) · Cancers · doi:10.3390/cancers11111815 · Cited by 20
Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma
Torres, A. N. B., Melchers, R. C., Grieken, L. V., Out‐Luiting, J. J., Mei, H., Agaser, C., Kuipers, T. B., Quint, K. D., Willemze, R., Vermeer, M. H., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.263251 · Cited by 20
KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
García-Robledo, J. E., Rosell, R., Ruíz-Patiño, A., Sotelo, C., Arrieta, O. G., Zatarain-Barrón, L., Ordóñez‐Reyes, C., Jaller, E., Rojas, L., Russo, A., et al. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666211066064 · Cited by 22
Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma
Deutzmann, A., Sullivan, D. K., Dhanasekaran, R., Li, W., Chen, X., Tong, L., Mahauad‐Fernandez, W. D., Bell, J., Mosley, A. R., Koehler, A. N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45128-y · Cited by 22
Jin, M., Shi, C., Hua, Q., Li, T. X., Yang, C., Wu, Y., Zhao, L., Yang, H., Zhang, J., Hu, C., et al. (2020) · Aging · doi:10.18632/aging.103264 · Cited by 20
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells
Liu, Z., & Gao, W. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.017 · Cited by 20
Tripathi, B. K., Hirsh, N. H., Qian, X., Durkin, M. E., Wang, D., Papageorge, A. G., Lake, R. G., Evrard, Y. A., Marcus, A. I., Ramalingam, S. S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00847-5 · Cited by 19
Targeting XPO1-Dependent Nuclear Export in Cancer
Kim, E., Mordovkina, D. A., & Sorokin, A. V. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922140140 · Cited by 20
Synthetic lethality: emerging targets and opportunities in melanoma
Thompson, N., Adams, D. J., & Ranzani, M. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12573 · Cited by 20
Use of Objective Metrics in Dynamic Facial Reanimation
Revenaugh, P. C., Smith, R. M., Plitt, M. A., Ishii, L. E., Boahene, K. D. O., & Byrne, P. J. (2018) · JAMA Facial Plastic Surgery · doi:10.1001/jamafacial.2018.0398 · Cited by 19
Metadata
- Authors
- Kim, J., McMillan, E., Kim, H. S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, J., Villalobos, P., Neggers, J. E., Mendiratta, S., Wei, S., Landesman, Y., Senapedis, W., Baloglu, E., Chow, C.-W. B., Frink, R. E., Gao, B., Roth, M., Minna, J. D., Daelemans, D., Wistuba, I. I., Posner, B. A., Scaglioni, P. P., & White, M. A.
- Affiliations
- Yonsei University (KR)
- The University of Texas MD Anderson Cancer Center (US)
- KU Leuven (BE)
- Karyopharm Therapeutics (United States) (US)
- Corresponding author
- White, Michael A.
- ORCID
- Venue
- Nature
- Published
- 2016-09-28
- Volume
- 538
- Issue
- 7623
- Pages
- 114-117
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5161658
- OpenAlex
- W2526506448
- Cited by
- 202
- References
- 36
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 22 · 2023: 13 · 2022: 23 · 2021: 18 · 2020: 27 · 2019: 23 · 2018: 32 · 2017: 25 · 2016: 1
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- RePEc: Research Papers in Economics (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute (P50CA070907, U01CA176284, RC2CA148225)
- National Institute of General Medical Sciences (T32GM008203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Structure and Function
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- CRM1, nuclear export, KRAS-mutant lung cancer, non-small cell lung cancer, synthetic lethality, NF-κB, IκBα, YAP, Hippo signaling pathway, verteporfin, drug resistance, RNAi screen, cell lines, KRAS inhibitors
- MeSH terms
- NF-KappaB Inhibitor alpha, Verteporfin, Hippo Signaling Pathway, YAP-Signaling Proteins, TEA Domain Transcription Factors, Exportin 1 Protein, Animals, Carcinoma, Non-Small-Cell Lung, Cell Nucleus, Cell Survival, DNA-Binding Proteins, Female, Genes, Lethal, Humans, Lung Neoplasms, Mutation, Nuclear Proteins, Phosphoproteins, Porphyrins, Transcription Factors, Signal Transduction, Proto-Oncogene Proteins p21(ras), NF-kappa B, Protein Serine-Threonine Kinases, Receptors, Cytoplasmic and Nuclear, Active Transport, Cell Nucleus, Xenograft Model Antitumor Assays, Karyopherins, RNA Interference, RNA, Small Interfering, Follistatin-Related Proteins, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
